Koers Aurinia Pharmaceuticals Inc. Toronto S.E.
Aandelen
AUP
CA05156V1022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 223 mln. 305 mln. 208 mln. | Omzet 2025 * | 288 mln. 394 mln. 268 mln. | Marktkapitalisatie | 727 mln. 995 mln. 678 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -6 mln. -8,21 mln. -5,6 mln. | Nettowinst (verlies) 2025 * | 58 mln. 79,36 mln. 54,09 mln. | EV/omzet 2024 * | 1,72 x |
Nettoliquiditeiten 2024 * | 344 mln. 471 mln. 321 mln. | Nettoliquiditeiten 2025 * | 390 mln. 534 mln. 364 mln. | EV/omzet 2025 * | 1,17 x |
K/w-verhouding 2024 * |
-91,5
x | K/w-verhouding 2025 * |
12,7
x | Werknemers | 300 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,55% |
Recentste transcriptie over Aurinia Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16-06-93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Robert Foster
FOU | Founder | 65 | 16-06-93 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16-06-93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26-06-19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,51% | 104 mld. | |
+3,22% | 97,42 mld. | |
+1,57% | 22,2 mld. | |
-16,53% | 21,23 mld. | |
-8,49% | 18,33 mld. | |
-42,33% | 16,35 mld. | |
-20,09% | 15,06 mld. | |
+5,47% | 13,98 mld. | |
+28,85% | 11,66 mld. |